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I was asked to lecture on the management of oral pre-
cancerous lesions, and to specifically focus on my per-
sonal approach to these lesions given 33-year’s of expe-
rience working with this particular population.
One thought kept coming back as I was preparing this 
presentation: “How is it possible that despite our having 
an early marker for oral cancer - namely, oral dysplasias 
we are no more effective today than we were 50 years 
ago in the fight against oral cancer? By this I mean that 
the mortality rates for oral cancer have not changed in 
spite of the professional awareness of precancerous le-
sions, and their potential risk of becoming malignant. 
Moreover, these lesions present to us the possibility 
of observable changes in the oral mucosa weeks and 
months prior to the onset of cancer. 
We could all agree that this is a unique and rare op-
portunity because few cancers, with the exception of 
perhaps skin cancer and melanomas, allow such easy 
access to them. Oral cancer and pre-cancerous lesions 
are so visible to the eyes that it is perplexing why we 
have failed so badly in defeating or even eradicating 
oral cancer through early diagnosis and treatment. One 
counter example to illustrate my point is the case of lip 
cancer, the only oral site where we have made major 
improvements both by significantly reducing its occur-
rence, and by increasing the cure rates. This success has 
been the result of extensive public campaigns report-
ing the effect of solar radiation on the lips, the ensuing 
recommendations for wearing sun block and hats, and 
early detection with timely treatment.
Several points must be addressed to understand the most 
conceivable reasons we have failed to do the same in the 
case of oral cancer. For instance, given the easy access 
to these pre-cancerous oral changes, and the relatively 
consistent oral appearance and sites predilection, we 
should have been empowering patients and other health 
care providers to look for these oral markers instead of 
having handed all the responsibility to the dental pro-
fession, namely the specialists in oral medicine, oral 
pathologist and oral surgery (1,2). Secondly, we have 
neglected to educate the public in regard to risk factors 
for oral cancer other than tobacco and alcohol abuse, 
such as oral sex (3), poor diet (4), and oral candidiasis 
(5,6), to list the most plausible risk factors.
In addition, another relevant question to us dental pro-
fessionals is whether we haven’t somehow neglected to 
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further scrutinize the natural course and/or behavior of 
this condition. Indeed, one of the most important as-
pects in fully understanding, and describing a disease, 
including its prognosis, and developing effective treat-
ment modalities is knowing their natural history.
Perhaps influenced or biased by the early connotations 
associated with pre-cancerous lesions, specifically oral 
leukoplakia, we have recklessly chosen to treat, at all 
cost, instead of trying to learn more about the behav-
ior of precancerous lesions, in particular erythroplakias 
and erythroplasias, even when we know that the risk of 
transformation is higher than for oral leukoplakia (7,8). 
The fact is that by doing so, we have made no prog-
ress in preventing oral cancer, and/or improve progno-
sis. Instead, we have continued to witness these lesions 
becoming cancerous before our eyes as we over-treat 
them. At present, there is no one test that can predict if a 
precancerous oral lesion will become full-blown cancer 
(9-12).
Indeed, the most serious problem in my view are (1) the 
insufficient understanding of the long-term behavior 
of these lesions, for instance which lesion will become 
malignant and/or when, and (2) the fact that we lack ef-
fective treatments. 
Some colleagues often claimed that it is unethical to 
carry out double-blind controlled clinical studies on pa-
tients with precancerous oral lesions, yet by continuing 
to do what we are now doing is equally unethical, in my 
view. In fact, we are not really improving the patient’s 
prognosis and it is unclear whether what we are doing 
is making the situation even worse. I must admit that in 
some cases we may postpone the development of cancer 
by few years. But even then we don’t know if it is be-
cause of our treatment or if this was going to be the case 
regardless of treatment (9,12).
Actually, one factor, which could explain our inability 
to determine which dysplasias, will become malignant 
and in need of treatment is the lack of a reliable molecu-
lar marker(s) (11,13,14). Moreover, an apparent reluc-
tance to use a uniform reporting system has precluded 
the universal standardization of our reporting (15,16) 
for multi-center epidemiologic and clinical studies.
Also, identifying key cellular/ molecular marker(s) will 
not only solve our diagnostic dilemmas but will lead 
into the development of new screening tools and thera-
pies. 
What we need to do next, I believe, is to pause and re-
focus our research objectives in order to gain a better 
understanding of what happens to these lesions when 
followed carefully, coupled with an evaluation of the 
presence and role played by local factors. Furthermore, 
we may have to revisit our nomenclature and classifica-
tion, and radically simplify it. We should ask ourselves 
“ Why don’t clinicians want to use it”. For example, 
the term “non-homogenous and homogenous leukopla-
kia” should be streamlined to “idiopathic leukoplakia” 
for white lesions, “idiopathic erythroplakia” for white 
and red lesions, and “idiopathic erythroplasia” for red 
lesions. Or perhaps we should limit it even further to 
white lesions (for idiopathic leukoplakia) and red le-
sions (for idiopathic erythroplasia and erythroplakia).
This will imply, to the reader, that clinicians have ex-
amined all plausible association, and that their presence 
is not accounted for by any local and/or systemic factor 
such as tobacco, trauma, alcohol, contact allergy, etc. 
stressing their seriousness. Also, this will facilitate or 
simplify the way in which clinicians select patients for 
their studies and how they report their findings.
At present there is no Gold Standard treatment for pre-
cancerous lesions that has been clinically proven to be 
effective (11). Most treatments have been hampered by 
the absence of a uniform reporting system for classi-
fication and staging of the disease, as previously em-
phasized by van der Waal (15) without which it will be 
almost impossible to objectively monitor any treatment 
outcome. Likewise, any molecular or genetic research 
will be meaningless without proper classification of the 
oral lesion (13).
From reviewing the literature my personal thought is 
that subjective criteria have largely been used to diag-
nose precancerous lesions, clinically and histologically. 
Clinicians as well as oral pathologists cannot agree on 
any specific pattern of histological findings to establish 
a consistent and reproducible diagnosis (16-19). We 
presently use the terms “mild”, “moderate”, “severe” 
dysplasia, which does not help the clinician in making 
an intelligent decision on when and how aggressively 
to treat. 
Pathologist like clinicians will have to simplify their 
classification system for it to be used (20). Clinicians 
likewise have not been able to agree on what is to be iden-
tified as “erythroplakia”, “lichenoid changes”, “lichen 
planus”, “ candidiasis” lichenoid-dysplasia” (11,21,22). 
To compound the problem, all molecular markers thus 
far have been inconclusive (10, 13,14), and/or too expen-
sive to be used routinely in any clinical setting.
With the exception of a few clinical and intervention 
studies (11) the majority of publications on the treat-
ment of precancerous lesions comprise pilot studies, 
case-series, reporting, reviews and letters (11). In other 
words, there are no well-designed clinical trials, sys-
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tematically tested and proven to be effective for precan-
cerous lesions.
All treatments seem to help one way or another depend-
ing on who conducted the study. So far the most popular 
seem to be the use of CO2 laser (23-25).
Clearly attested for in the literature, and confirmed by 
my own personal experience, CO2 laser provides the 
easiest, cleanest and most convenient approach to pa-
tients and clinicians. Yet, we need to be aware of the 
fact that even this procedure has not been universally 
standardized. Further studies should at least consider 
randomizing patient selection to avoid clinician’s selec-
tion bias, and should adhere to strict disease classifica-
tion guidelines (11).
In CO2 laser protocols, the only constant variable is that 
we use CO2 laser; any other aspect of the treatment is 
solely a decision made by the clinician. Issues regarding 
patient selection, surgical margins, required to guar-
antee disease control, the depth of the surgical sample, 
etc, are all arbitrarily determined by the clinician, and/
or surgeon. So, whether or not you have a positive out-
come depends primarily on the clinician’s experience 
in selecting the right lesion, and properly mapping it at 
the time of the surgery, as well as having a skilled and 
experienced surgeon performing the procedure. This 
could explain the discrepancy in outcomes from differ-
ent case-series published in the literature (24,25). 
As I mentioned earlier, we need to systematically col-
lect information on other, local factors such as candidi-
asis, HPV associated lesions (3,26), nutrition, and xe-
rostomia (27).
Until we have a better understanding of the course of 
precancerous lesions, specifically erythroplakias and 
erythroplasias, and can develop a reliable diagnostic 
instrument, we will not be able to accurately evaluate 
treatment outcome. Any outcome whether favorable or 
not could be the result of chance, misdiagnosis, over 
-diagnosis, or under-diagnosis, and not necessarily the 
effectiveness of a treatment approach.
In summary, we need to work toward the identifica-
tion of cellular/molecular makers to help in diagnosis 
(28,29), and therapies.
In parallel, we must try to educate the population not 
only about the risk factors associated with oral cancer 
but also the most common clinical sites, and appearance 
of oral pre-cancerous lesions and oral cancer.  Prelimi-
nary data indicates (1,2) that there is a period of approx-
imately 7-month from the time a patient becomes aware 
of a problem in their mouth to the time of treatment. 
Given the success Dermatologists have had in educat-
ing health care providers and the public on the risk fac-
tors and clinical appearance of skin cancer including 
melanoma, there is all reasons to believe that we the oral 
health care providers could achieve the same success.
The management approach to precancerous lesions 
which I have developed consist of the following steps 
and/or guidelines: Obtain detail information on the 
family history of cancer, medical history  (of any HPV-
associated lesions), and thorough social history (use of 
tobacco, alcohol, and/or recreational drugs)
1. Perform a careful oral examination and do record by 
photos any oral changes.
2. Work out a provisional diagnosis, which will help in 
determining biopsy site (s). Use toloudine blue to map 
and/or help in selecting the most appropriate biopsy site. 
Consider all high risk sites (lateral tongue, floor of the 
mouth, soft palate) for biopsy.
3. When candida is suspected, treat prior to biopsy. 
For patients with a positive history of oral candidiasis 
at baseline, identify any underlying medical problems 
(diabetes), and referred for treatment. In patients other-
wise healthy look for local factors (xerostomia).
4. Always compare patient’s history with clinical find-
ings and evaluate the significance of such findings 
(erythroplakia in a young woman, with unknown risk 
factors on lateral tongue). Some findings should alert 
the clinician as to the severity of the situation, and will 
help in determining treatment protocol, frequency of 
clinical visits and biopsies.
5. Evaluate every lesion in the mouth, and re-access on 
each follow up visit. Patient can develop new lesions. I 
always keep in mind that a patient may have different 
type of lesions at the same time.
6. First order of treatment must include stabilization of 
the mouth (treat for dryness, and fungal infection). In-
sist on the importance of good oral hygiene, and good 
nutrition.
7. Use toloudine blue to monitor disease instead of per-
forming un-necessary biopsies.
8. Use CO2 laser in cases involving severe dysplasia 
where significant changes are seen over time, and the 
patient is symptomatic. Prior to laser take a biopsy, and 
properly orient sample for further evaluation of the le-
sion. When thinking of margins use same principles as 
for cancer removal. 
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